Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

被引:0
作者
D Roberts
J Schick
S Conway
S Biade
P B Laub
J P Stevenson
T C Hamilton
P J O'Dwyer
S W Johnson
机构
[1] University of Pennsylvania Cancer Center,Department of Medical Oncology
[2] Fox Chase Cancer Center,undefined
来源
British Journal of Cancer | 2005年 / 92卷
关键词
cisplatin; drug resistance; ovarian cancer; microarray; Stat1;
D O I
暂无
中图分类号
学科分类号
摘要
Platinum-based chemotherapeutic regimens are ultimately unsuccessful due to intrinsic or acquired drug resistance. Understanding the molecular basis for platinum drug sensitivity/resistance is necessary for the development of new drugs and therapeutic regimens. In an effort to identify such determinants, we evaluated the expression of approximately 4000 genes using cDNA microarray screening in a panel of 14 unrelated human ovarian cancer cell lines derived from patients who were either untreated or treated with platinum-based chemotherapy. These data were analysed relative to the sensitivities of the cells to four platinum drugs (cis-diamminedichloroplatinum (cisplatin), carboplatin, DACH-(oxalato)platinum (II) (oxaliplatin) and cis-diamminedichloro (2-methylpyridine) platinum (II) (AMD473)) as well as the proliferation rate of the cells. Correlation analysis of the microarray data with respect to drug sensitivity and resistance revealed a significant association of Stat1 expression with decreased sensitivity to cisplatin (r=0.65) and AMD473 (r=0.76). These results were confirmed by quantitative RT–PCR and Western blot analyses. To study the functional significance of these findings, the full-length Stat1 cDNA was transfected into drug-sensitive A2780 human ovarian cancer cells. The resulting clones that exhibited increased Stat1 expression were three- to five-fold resistant to cisplatin and AMD473 as compared to the parental cells. The effect of inhibiting Jak/Stat signalling on platinum drug sensitivity was investigated using the Janus kinase inhibitor, AG490. Pretreatment of platinum-resistant cells with AG490 resulted in significant increased sensitivity to AMD473, but not to cisplatin or oxaliplatin. Overall, the results indicate that cDNA microarray analysis may be used successfully to identify determinants of drug sensitivity/resistance and future functional studies of other candidate genes from this database may lead to an increased understanding of the drug resistance phenotype.
引用
收藏
页码:1149 / 1158
页数:9
相关论文
共 196 条
[1]  
Arbel R(2003)Inhibitors that target protein kinases for the treatment of ovarian carcinoma Am J Obstet Gynecol 188 1283-1290
[2]  
Rojansky N(1980)1,2-Diaminocyclohexane platinum derivatives of potential clinical value Recent Results Cancer Res 74 146-155
[3]  
Klein BY(2001)Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells Oncogene 20 7925-7934
[4]  
Levitzki R(1995)Substitution of chloroform with bromochlorophane in the single-step method of RNA isolation Anal Biochem 225 163-164
[5]  
Hartzstark Z(1987)Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction Anal Biochem 162 156-159
[6]  
Laufer N(1972)New platinum complexes with anti-tumor activity Chem Biol Interact 5 415-424
[7]  
Ben-Bassat H(2000)Three differentially expressed survivin cDNA variants encode proteins with distinct apoptotic functions Blood 95 1435-1442
[8]  
Burchenal JH(1999)Oxaliplatin: a new therapeutic option in colorectal cancer Semin Oncol 26 647-662
[9]  
Irani K(2002)An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines Cancer Res 62 1139-1147
[10]  
Kern L(2000)JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells Br J Haematol 109 823-828